Modality
Gene Therapy
MOA
Cl18.2
Target
GPRC5D
Pathway
Apoptosis
DMDPSP
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
~Dec 2017
→ ~Mar 2019
Phase 3
Jun 2019
→ Sep 2030
Phase 3Current
NCT05476019
529 pts·PSP
2019-06→2030-09·Recruiting
NCT06715940
2,568 pts·PSP
2020-08→2026-02·Recruiting
3,097 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-062mo agoPh3 Readout· PSP
2030-09-024.4y awayPh3 Readout· PSP
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2026-02-06 · 2mo ago
PSP
Ph3 Readout
2030-09-02 · 4.4y away
PSP
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05476019 | Phase 3 | PSP | Recruiting | 529 | EASI-75 |
| NCT06715940 | Phase 3 | PSP | Recruiting | 2568 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |